Showing results for Diabetes

Roland Herzog, PhD and Sandeep Kumar, PhD

Researchers reveal uncharted liver-focused pathway in gene therapy immune responses

Indiana University School of Medicine researchers have uncovered vital insights regarding a liver trigger that blocks an undesired immune response from gene therapy, surprisingly resulting in the activation of specific immune cells, despite the liver's typical role in suppressing immune responses. The findings, published in Molecular Therapy, may pave the way for change in immunomodulation strategies for desired and long-lasting effects of gene therapy.

IU School of Medicine | Dec 07, 2023

Repurposed drug offers new potential for managing type 1 diabetes

A recent study led by Indiana University School of Medicine in collaboration with the University of Chicago Medicine presents exciting future possibilities for the management of type 1 diabetes and the potential reduction of insulin dependency.

IU School of Medicine | Nov 01, 2023

Researcher applies a wound dressing to a man's foot.

Defective closure of diabetic foot ulcers is associated with higher risk of wound recurrence

Results from a new study of diabetic foot ulcers and the risk of wound recurrence can help health care workers measure the likelihood that the wound will reopen in the future. These findings are likely to lead to further studies aimed at decreasing amputation rates for the tens of millions of people with diabetes in the United States.

IU School of Medicine | Jun 26, 2023

IU diabetes researchers discover new use for high blood pressure medication called verapamil

A clinical study conducted by Indiana University School of Medicine researchers revealed that oral verapamil, a readily available and commonly used drug to treat high blood pressure and heart conditions, can also improve the pancreas’ insulin secretion in children with newly-diagnosed type 1 diabetes (T1D).

IU School of Medicine | Mar 01, 2023

IU research contributes to first FDA-approved drug to delay onset of type 1 diabetes

Researchers at Indiana University School of Medicine are celebrating Federal Drug Administration approval of teplizumab, a new immunotherapy drug that delays the onset of type 1 diabetes in at-risk individuals by an average of almost three years.

IU School of Medicine | Nov 21, 2022

IU School of Medicine-led study shows human induced pluripotent stem cells improve visual acuity, vascular health

Researchers are investigating novel regenerative medicine approaches to better manage vascular health complications from type 2 diabetes that could someday support blood vessel repair in the eye among diabetic patients with early retinal vascular dysfunction.

IU School of Medicine | Mar 10, 2022

Synthetic hinge could hold key to revolutionary “smart” insulin therapy

For people with diabetes who are insulin dependent, glycemic control is a full-time job. But what if their medication could do the work for them—an insulin whose activity in the bloodstream responds to the blood glucose levels and adjusts accordingly?

IU School of Medicine | Jul 29, 2021

100 years after the discovery of insulin, scientists reflect on the history, trajectory of diabetes research

One hundred years ago, Type 1 diabetes was a fatal disease. Then in 1921, a contemporary medical miracle: the discovery of insulin and its role in blood glucose regulation.

IU School of Medicine | Jul 28, 2021

Scientists call on professional community to support women in diabetes research

A group of leading scientists is holding a mirror to the diabetes research community and calling for the improved support of its female constituents. Linda DiMeglio, MD, MPH, of Indiana University School of Medicine and Mark Atkinson, PhD, of the University of Florida, led a deep dive into the historical representation of women in the diabetes research community and that of women in influential positions among four major diabetes organizations.

IU School of Medicine | Jul 20, 2021

An evolutionary cul-de-sac: Study suggests most humans are vulnerable to Type 2 diabetes

Scientists have found that insulin has met an evolutionary cul-de-sac, limiting its ability to adapt to obesity and thereby rendering most people vulnerable to Type 2 diabetes. A recent study from scientists at Indiana University School of Medicine, the University of Michigan and Case Western Reserve University has determined that the sequence of insulin has become entrenched at the edge of impaired production, an intrinsic vulnerability unmasked by rare mutations in the insulin gene causing diabetes in childhood

IU School of Medicine | Nov 02, 2020